Introduction
Due to its short half-life, p53 levels are low in normal cells. There, p53 is activated by cellular stress which leads to stabilization and nuclear accumulation of p53 and the expression of several target genes, including mdm2 and p21 WAF1/CIP1/SDI1 (p21) (Prives, 1998) . The p53 target gene mdm2 encodes a p53-speci®c E3 ubiquitin ligase (Honda et al., 1997) which controls the stability of the p53 tumour suppressor protein in an autoregulatory feedback loop. In normal cells, phosphorylation of p53 at speci®c serine residues in response to cellular stress or DNA damage prevents p53 degradation (Prives, 1998) . Certain human tumours like neuroblastoma (NB) (Moll et al., 1995 , breast cancer (Moll et al., 1992) , colon cancer (Bosari et al., 1995) and retinoblastoma (Schlamp et al., 1997) , as well as normal mouse embryonic stem cells (Aladjem et al., 1998) were reported to accumulate wild-type p53 in the cytoplasm. Nuclear localization is essential for p53's activity as a transcription factor (Shaulsky et al., 1991a,b) . Therefore we investigated various human NB cell lines reported to exhibit`cytoplasmic sequestration' of p53 . We demonstrate that the perceived subcellular localization of p53 is dependent on the antibody against p53 used for detection, both in established NB cell lines and in NB tissue. Especially the antibodies PAb1801 and DO-1 show marked dierences in the localization of p53. Our data also indicate that in NB cells the gene products of p53 target genes mdm2 and p21 are not produced, nor induced after DNA damage, despite a slight increase in p53 protein levels.
This could provide new insight into the mechanism of oncogenic transformation in NB, despite p53 wildtype genes.
Results

Apparent subcellular localization of p53 in the cytoplasm of NB cell lines depends on antibody used for detection
We investigated three human NB cell lines, SK-N-SH, LAN-5 and CHP134, described to contain wild-type p53 protein exclusively in the cytoplasm, sometimes as so-called`punctate structures' . To exclude clone variability, we obtained each cell line from at least two dierent sources (see Materials and methods). Control cell lines were the human MCF-7 and the murine ®broblast line C3H10T, both containing functional wild-type protein which accumulates to immunologically detectable levels after DNA damage. p53-negative control cells were murine p53 7/7 ®broblasts and the human SAOS-2 cell line. Figure 1a shows indirect immuno¯uorescence assays of unstressed cells with antibodies directed against dierent epitopes of human p53: DO-1 (aa 21 ± 25, human-speci®c, Cohen et al., 1998; Craig et al., 1999a,b) , PAb1620 (aa 88 ± 109, speci®c for human p53 in the DNA-binding conformation, Foster et al., 1999) , PAb240 (aa 210 ± 219, speci®c for p53 in thè latent' conformation; Ullrich et al., 1992; Foster et al., 1999 ), PAb421 (aa 370 ± 378, panspeci®c, Milner, 1994 Waterman et al., 1998) and CM-1 (rabbit polyclonal anti-human-p53 serum). Mouse normal serum was used as a control for background staining.
As reported, p53 was located predominantly in the cytoplasm of all NB cell lines. However, when using the antibodies DO-1, PAb240 or CM-1, 1 ± 10% of the cells also exhibited nuclear staining. For documentation ( Figure 1 ) we selected those areas of each slide which contain both nuclear and cytoplasmically located p53. Interestingly, PAb1620 showed only weak cytoplasmic and no nuclear staining, suggesting that p53 was not in a DNA-binding conformation. Also with PAb421, recognizing a modi®cation-sensitive epitope at the C-terminus, p53 could be detected in all cell lines, when used at higher concentrations (10 mg/ml instead of 0.1 ± 1 mg/ml, also: Danks et al., 1998) . Therefore the epitope does not appear to be`masked', as previously assumed Zaika et al., 1999) . As expected, p53 7/7 mouse ®broblasts exhibited only background staining, while unstressed MCF-7 cells showed occasional nuclear accumulation of p53 (*1% of all cells in each assay). AW-1 cells, an SK-N-SH subclone containing a point mutation in p53, are the only cells that exhibit constitutively nuclear accumulation of p53.
Punctate structures' were only detectable with PAb1801 (recognizing aa 46 ± 55). However, these structures could also be seen sometimes in the p53-negative cell line SAOS-2 and even the p53 7/7 murine ®broblasts ( Figure 1b and Danks et al., 1998) , though PAb1801 is reportedly speci®c for human p53 (Bonsing et al., 1997; DraneÂ et al., 1997) . Other anti-p53 antibodies gave no signal in these p53-negative cell lines, as expected ( Figure 1a and data not shown). We conclude that PAb1801 also reacts with a protein other than p53 which is located in the cytoplasm of both the NB and p53-negative control cell lines.
p53 staining pattern in histological sections also depends on the antibody used Since these results diered from published data , we examined four undierentiated tumour samples from pre-treatment patients. Figure 2 shows a representative immunohistological assay for adjacent NB tissue sections with the antibodies DO-1 and PAb1801. While PAb1801 here also results in cytoplasmic and nuclear staining, DO-1 localizes p53 exclusively in the nucleus of NB cells of all cases (4/ 4). Positive and negative controls gave the expected results (data not shown, see Materials and methods).
Cell fusion experiments let`cytoplasmic retention factor' appear unlikely
The goal of the experiments was to determine whether the NB phenotype of`cytoplasmically sequestered' wtp53 is dominant or recessive, and if a hypothetical retention factor' postulated by Moll et al. (1996) could be titrated out in merged cells by additional p53 from the`normal' fusion partner that contains no such retention factor. NB cells and murine C3H10T cells were fused, after previously being marked with red or blue Fluorospheres 2 . Fusion was induced by PEG and resulted in polynucleated cells having both human (NB-derived) and murine nuclei that remain distinct. The fused cytoplasm contains human and murine wildtype p53 from NB and C3H10T cells in dierent amounts (NB cells contain higher amounts than untreated C3H10T cells). A hypothetical`retention factor' from NB cells would also be contained in the merged cytoplasm.
Fused cells were ®xed and analysed by immunouorescence 2, 4, 6 and 12 h after fusion, respectively. Two hours after fusion, most of the p53 present in the heterokaryons should still be derived from the original NB cells, while 12 h would allow for a complete turnover of even the NB-p53 (which has an increased half-life). All pictures in Figure 3 are from the 6 h experiment.
Results showed no clear pattern for p53 distribution whatsoever and, surprisingly, no signi®cant dierence between the various points in time either (other than a general increase in p53 amounts which likely is due to the cellular stress fusion constitutes). There was no homologous distribution of p53 among the nuclei of fused cells, though a retention protein should aect all p53 in the merged cytoplasm the same way ± either hold it all back, or be titrated out by over¯ow of p53 and thus allow`free' p53 to enter all nuclei.
However, all conceivable combinations could be seen: Cells with only one p53-positive nucleus, containing all the p53 (as in row 1, column 3 of Figure 3 ), cells with a strong cytoplasmic¯uorescence yet also containing one or more p53-positive nuclei (as in row 2, column 3), only one of several nuclei was p53-positive or only one of several was p53-negative. Discerning the human and murine nuclei morphologically or with an antibody speci®c for human nucleoli (Ab1277, not shown) showed that it made no dierence for the seemingly random distribution of p53 among a heterokaryon's nuclei and, most importantly, that p53 can in principle enter the nucleus of an NB cell (row 1 and 2 both show human nuclei containing p53).
Another surprise were results from control experiments with the AW-1 subclone (SK-N-SH cells with mutated p53). Even there, p53 seemed distributed at random among the heterokaryons' various nuclei, Figure 1 Immuno¯uorescence assays with NB and control cells (a) with anti-p53 antibodies DO-1 (0.1 mg/ml), PAb1620 (hybridoma supernatant, 1 : 10), PAb240 (1 mg/ml), PAb421 (10 mg/ml), CM-1 (polyclonal anti-p53 rabbit serum, 1 : 100) or (b) PAb1801 (1 mg/ml). Scale bar: *10 mm despite the fact that prior to fusion it was all contained in the AW-1 nuclei. After fusion all the p53 could even end up in one of the murine nuclei (row 3 of Figure 3 ).
We thus concluded that cytoplasmic localization of p53 in NB cells is not a static phenomenon, caused by some cytoplasmic`anchor protein', but rather that p53 shuttles between the cellular compartments. It can enter the nuclei of NB cells freely (as already hinted by the subpopulation of NB cells with nuclear p53 we always detected in immuno¯uorescence, see Figure 1 ). So we suggest that nuclear export of p53 outweighs nuclear import in NB cells. The next step was therefore ; both visible as small, bright dots. White arrows indicate human (thus NB-derived) nuclei, black arrows indicate murine nuclei. Scale bar: *10 mm to look at the conformation(s) of p53 in NB cells and the possible in¯uence of p53 conformation on its subcellular localization.
Different species of p53 are immunoprecipitated from NB cell lysates
For sensitive qualitative detection of dierent conformations p53 was enriched by immunoprecipitation from large samples and then subjected to SDS ± PAGE and Western blot analysis. Figure 4aI shows a Western blot of p53 from NB and control cells, untreated or treated with mitomycin C (mitoC, 10 mg/ml, 6 h). p53 was immunoprecipitated with PAb421 and visualized on blots with sheep polyclonal antibody Ab-7. A p53 band was detected in all lanes, con®rming that the PAb421 epitope is not masked' in NB cells. Note that because of prior enrichment by immunoprecipitation, under potentially saturating conditions, the band intensity does not necessarily mirror the original p53 protein levels in the cell. As a control for the cellular p53 stress response Western blots from unenriched cell lysates are added ( Figure 4II ). In these controls, cells treated with either mitoC, short wave (254 nm) ultraviolet light (UVC, 20 J/m 2 , 6 h prior to analysis) or H-7, a potent serine/threonine protein kinase inhibitor (100 mM, 24 h), exhibited a`normal' p53 accumulation response as repeatedly described (e.g. Smart et al., 1999) . The only exception are the AW-1 cells that express constitutively elevated levels of mutant p53.
p53 is present in both`mutant' and`wild-type' conformations in NB cells (Figure 4b ), as demonstrated by immunoprecipitation (followed by SDS ± PAGE and Western blot analysis, as above, Figure  4aI ) with PAb1620 and PAb240, which are directed against conformational epitopes of p53. Again it has to be noted that the aim of the experiment was to detect even minuscule amounts p53 in its dierent conformations, not quantify them. We thus started the immunoprecipitation with very large samples and potentially saturating conditions, so that no conclusion about original p53 levels in the cells can be drawn from this experiment. 
Influence of p53 conformation on p53 localization
While culturing SK-N-SH cells a subpopulation which exhibited exclusively nuclear p53 was discovered, subcultured and denoted AW-1. Sequencing (see Materials and methods) revealed a point mutation in p53 at Cys1764Ser within the zinc ®nger motif whose loss can lead to a conformational shift (Meplan et al., 1999) . To test the hypothesis that p53 localization is in¯uenced by disturbance of the zinc ®nger motif and its resultant change of conformation, we treated NB cells with N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN, a zinc chelator; Verhaegh et al., 1998) , Meplan et al., 1999) and mitoC (induces DNA damage). Figure 5 demonstrates that removal of zinc from NB cells by treatment with TPEN has the same eect on p53 subcellular localization as the p53 mutation in the AW-1 subclone: p53 accumulates in the nuclei, probably due to a conformational shift that disturbs nucleo-cytoplasmic shuttling. A similar eect can be seen when treating cells with Cd 2+ , which competes with Zn 2+ for the binding site within the zinc-®nger domain and due to its larger size also disturbs its conformation. Ten mg/ml mitoC are necessary to achieve similar p53 accumulation and apparent`translocation' to the nucleus. Obviously, p53 conformation determines whether or nor it will be exported from the nucleus.
P53 can be induced to be DNA-binding competent in NB cells p53 DNA-binding competence in treated or untreated NB was analysed by EMSA. Hupp et al. (1992) found that p53 is activated by binding to PAb421, C-terminal deletion or phosphorylation at Ser392 by casein kinase II. Both inactive and active p53 cannot be shifted by DO-1 alone, but a combination of PAb421 plus DO-1, or PAb421 alone, can supershift activated p53 (Hupp et al., 1992 and Figure 6, MCF-7 control) . p53 from lysates from untreated NB or MCF-7 control cells is not shifted by either PAb421 or DO-1 (not shown) or a combination of both (Figure 6 ), indicating that the accumulated p53 in unstressed NB cells is inactive. However, in mitoC-treated NB cells either PAb421 or DO-1 or both in combination can shift DNA-bound p53. This demonstrates that p53 can be activated to bind DNA in these NB cells. AW-1-derived p53 cannot bind to DNA, since it is mutated (negative control, Figure 6 ).
p53 is transcriptionally inactive in NB cells
DNA binding in itself is an indication but not a proof of transcriptionally active p53. p53 was activated in other NB cells by high doses of g-irradiation and in these cells the p53 target gene products p21 and MDM2 are synthesized (Goldman et al., 1996) . Since dierent pathways are activated in dierent cells by dierent cellular stresses (Agarwal et al., 1998; Oren, 1999) , we looked at p53 target gene induction in NB cells under various conditions. NB and MCF-7 control cells were treated with mitoC, UVC or H7 as above. AW-1 cells served as negative control. Lysates were subjected to SDS ± PAGE and Western blot analysis for human MDM2, using the more sensitive SuperSignal 1 chemoluminescent substrate (Pierce, IL, USA). Only in the wild-type ) on the localization of p53 in NB cells (CHP134, LAN-5, SK-N-SH) and a control cell (MCF-7). A DNA-damaging agent (mitoC) serves as control. Cells were treated for 6 h with the given concentrations and stained with the CM-1 polyclonal anti-p53 antibody. Scale bar: *10 mm p53-expressing MCF-7 cells was a signi®cant induction of MDM2 found (Figure 7a) .
Similarly, the NB cells did not accumulate p21 after treatment with cisplatin, another DNA-damaging and p53-activating agent (Merlin et al., 1998) . Both wildtype p53 control cell lines, MCF-7 and C3H10T accumulated p21 after treatment, as demonstrated by TSA-direct 1 enhanced immuno¯uorescence ( Figure  7b) .
Staining of the human NB tissue sections described above with antibodies against MDM2 or p21 was negative in 4/4 cases (data not shown).
In addition, we directly measured inducible p53 transcriptional activity in NB cells: pGL2NA(mdm2)-luc, a p53-dependent reporter plasmid that expresses luciferase under control of the mdm2 gene promoter sequence (Barak et al., 1993) , was transfected. Normalized luciferase activity was measured 24 h after transfection in cells treated with mitoC (6 h prior to analysis) or left untreated. All NB cell lines as well as the AW-1 p53 mutant showed no luciferase activity. MCF-7 control cells exhibited signi®cant p53 activity untreated and a strong induction after treatment (Figure 7c ). Additional controls were the SV40-transformed cell lines BEAS (human) and C57SV (murine) that both express high amounts of SV40 large T-antigen, rendering their wild-type p53`inactive' (Technau et al., 2001) . Unlike NB cells the latter have *1% of measurable residual p53 activity, compared to the MCF-7 control cells.
Obviously p53 transcriptional activity is impaired in NB cells as far as MDM2 and p21 induction is concerned.
Discussion
Since p53 is a transcription factor, nuclear localization is essential for its function (Shaulsky et al., 1991b) . We analysed a panel of NB cells which reportedly accumulate wild-type p53 in the cytoplasm to gain insight in the mechanism of p53 shuttling in these cells.
However, immuno¯uorescence assays conducted with ®ve dierent antibodies against p53 showed that p53 is not localized exclusively in the cytoplasm of the NB cells. Up to 10% of unstressed SK-N-SH, LAN-5 or CHP134 exhibited nuclear localization of p53. Only the monoclonal antibody PAb1801 stained`punctate structures' in the cytoplasm. Since this antibody also gave positive staining in p53-negative cells, PAb1801 is obviously not exclusively speci®c for p53 and therefore unsuitable for p53 localization. This conclusion is supported by the detection of proteins unrelated to p53 using PAb1801 (Kaltho et al., 1993; DraneÂ et al., 1997; Danks et al., 1998) . Moreover the immunohistological assays with NB tissue sections con®rm these results obtained with NB cells. p53 was also found in NB cells with PAb421. Obviously the epitope is not`masked' by a`cytoplasmic retention factor'. A dierence in phosphorylation Figure 6 p53 from mitoC-treated NB cells binds to its cognate sequence and can be shifted with either PAb421, or DO-1, or a combination of both. NB and control cells were treated with 10 mg/ml mitoC for 6 or 12 h. Samples containing equal amounts of total protein were incubated with either 50 ng PAb421, or 50 ng DO-1, or both antibodies. Arrowheads indicate the position of shifts caused by DO-1+PAb421, DO-1, and PAb421 (in descending order). Figure shows the upper half of the EMSA for samples prepared from cells treated for 12 h; shifts were similar at 6 h status at Ser376 (Waterman et al., 1998) seems to account less for this discrepancy than the concentration of PAb421 used for detection.
Instead, as cell fusion experiments ( Figure 3 ) and eects of leptomycin B (Wol et al., 1999) demonstrate, predominantly cytoplasmic accumulation of p53 in NB cells is probably due to hyperactive nuclear export via p53's own nuclear export sequence (Stommel et al., 1999) . Komarova et al. (1997) suggest that p53 localization in the nucleus might be cell cycledependent, which could account for the distribution patterns we observed in heterokaryons a few hours after fusion.
The most likely explanation seems that`cytoplasmic sequestration' of p53 in NB is a property of p53 itself, probably due to aberrant modi®cations and/or a shift in protein conformation. This might be overcome in fused cells by formation of human/murine heterooligomers, which may function normally again. It is known that human and murine p53 can form dimers and tetramers freely (Komarova et al., 1997; McLure and Lee, 1998) . Accordingly, in our experiments it was never possible to discern human and murine p53 in fused cells by use of antibodies speci®c for one of the p53 species (not shown).
According to immunoprecipitation with various antibodies p53 is present in dierent conformations in NB cells and it can be induced to even higher levels by treatment with mitoC or other agents. After treatment, p53 accumulated in the nucleus. Nuclear accumulation in NB cells was also observed if the p53 protein conformation was changed by: (i) mutation at the zinc®nger motif; or (ii) chemical disturbance of this motif; or (iii) DNA damage. In conclusion, the localization of p53 seems to depend primarily on its conformation.
Despite p53 being wild-type, its accumulation in the nucleus and DNA-binding capability after mitoC treatment, p53 seems to be transcriptionally inactive in the NB cells investigated, at least for the production of target gene products p21 and MDM2. The discrepancy between DNA-binding capability and transcriptional inactivity could be due to any of several factors regulating p53 transcriptional activity: Lack of or`incorrect' modi®cation of p53, lack of interaction with other factors involved in the transcriptional process (Levine, 1997; Prives, 1998; Oren, 1999) or the DNA topology of the p53 target genes .
Recently it was found that Ser15 phosphorylation is important for p53-dependent transactivation as this increases p53-binding to the p300 co-activator protein (Dumaz and Meek, 1999) . p53 in NB cells was phosphorylated at Ser392, but not Ser15, after mitoC treatment (unpublished data). Therefore we suggest that p53 is incapable of inducing transcription of its target genes because of its inability to assume its place in the transcription machinery. McLure and Lee (1998) presented a model for p53 tetramerization and DNAbinding as`a pair of clamps ' and Stommel et al. (1999) suggested that the nuclear export sequence of p53 is masked when p53 binds to DNA as a tetramer. Because of its`inappropriate' conformation in NB cells, p53 might be unable to form tetramers and is therefore continuously exported from these cells. Maki (1999) presented evidence that oligomerization is also necessary for p53 to be eciently ubiquitinated by MDM2. This would explain why p53 in NB cells cannot be degraded even by externally introduced MDM2.
In untreated NB cells p53 was predominantly in a non-DNA-binding conformation (PAb240-positive, Figure 1a ) and was therefore exported from the nucleus. This conformation is characteristic of socalled`latent' p53 which can also be found in the cytoplasm during development in embryonal stem cells (Aladjem et al., 1998) and during part of the cell cycle (Shaulsky et al., 1990) . Since MDM2 was not present in either unstressed or mitoC-treated cells, this also means that p53 can shuttle between the cytoplasmic and the nuclear compartment without the help of MDM2. However, p53 interaction with MDM2 in the nucleus might be necessary for p53 degradation (Tao and Levine, 1999) .
Another indication that p53 might be in a conformation refractory to integration into the transcription machinery comes from the EMSA data: p53 can be shifted by DO-1 alone in mitoC-treated NB cells, while p53 from mitoC-treated control cells can be shifted only after stabilization with PAb421 ( Figure 6) . The epitope at which DO-1-binding to p53 occurs is only accessible if p53 is dephosphorylated at Ser20. Phosphorylation at Ser20 after DNA-damage weakened the interaction of p53 with MDM2 in vitro (Chehab et al., 1999) , hinting at another reason why in NB cells p53 might be undegradable by exogenously introduced MDM2. In NB cells, the DO-1 epitope is accessible in unstressed cells (Figure 1 ) and after DNAdamage ( Figure 6 ). While modi®cations at other residues make NB-derived p53 capable of binding DNA, its lack of modi®cation at Ser20, which leads to the DO-1-shift in Figure 6 , might prevent interaction with other molecules necessary for transcription from taking place.
A p53 protein locked in an aberrant conformation would have far-reaching consequences for its interaction with co-activators (Ashcroft and Vousden, 1999), co-repressors (May and May, 1999) , and molecules involved in DNA-repair (Albrechtsen et al., 1999) , explaining the many genetic lesions occurring in neuroblastomas despite p53 wild-type genes (Schwab, 1999) .
In summary, we conclude that the phenotypic localization defect' of p53 visible in the NB cells examined in this study is a consequence of aberrant modi®cation of p53 but as yet to be identi®ed upstream acting factors. This aberrant modi®cation results in at least partial transcriptional inactivity, hyperactive nuclear export and accumulation of p53 due to lack of MDM2. The NB cells examined in this study present an interesting model for investigation of the upstream acting factors in¯uencing p53 localization and activity.
Materials and methods
Cell culture
Cells were grown under standard conditions in RPMI 1640 medium containing 10% fetal calf serum. NB cell lines were: CHP134 (from: Dr Manfred Schwab, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany and Centro di Biotechnologie Avanzate (ICLC), Genoa, Italy), LAN-5 (from CAMR, Centre for Applied Microbiology and Research, Salisbury, England and ICLC) and SK-N-SH (from Dr Manfred Schwab, DKFZ, American Type Culture Collection (ATCC) and ICLC). As control cells we used MCF-7 (breast carcinoma, p53 wild-type, from: Center for Tumor Biology, Freiburg, Germany), SAOS2 (osteosarcoma, p53-negative, from ATCC), p53 7/7 ®broblasts (established from newborn p53-de®cient mice, TSG-p53, GenPharm International) and C3H10T (non-oncogenic mouse ®bro-blasts, Siegel et al., 1995) .
Immunofluorescence assay
Cells were cultivated on coverslides and immuno¯uorescence performed as described (Wol et al., 1997) . To detect p53, either the monoclonal antibodies DO-1, PAb1801, PAb240, or PAb421 (all from Calbiochem-Novabiochem, Schwalbach, Germany), PAb1620 (from hybridoma cultures, our laboratory: Hebel et al., 1986) , a sheep polyclonal anti-p53 antibody (Ab-7, Calbiochem-Novabiochem) or a polyclonal rabbit anti-p53 antibody (CM-1, gift from David Lane, Dundee, Scotland) were used. Secondary antibodies were biotin antimouse IgG (Dianova, Hamburg, Germany) or biotin antirabbit IgG (Dianova), followed by streptavidin-¯uorescein (Dianova). For detection of p21 with Ab-1 (CalbiochemNovabiochem), incubation with the secondary antibody was followed by detection with Tyramide Signal Ampli®cation (TSA-direct 1 , Kit # NEN701, Du Pont NEN, Bad Homburg, Germany). For MDM2 detection we used Ab-1 (CalbiochemNovabiochem).
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Staining of nuclei
Fifty ng/ml of the DNA-speci®c dye, 4',6-diamidino-2-phenylindole (DAPI; Sigma, Deisenhofen, Germany), were added to PBS in the ®nal immuno¯uorescence washing step.
Sequence analysis of p53
Cells were grown to con¯uence and genomic DNA prepared using the InViSorb DNA Kit III (InViTek, Berlin, Germany) according to the manufacturer's instruction. PCR was performed using nested primers after initial ampli®cation of a PCR-fragment containing exons 5 ± 9. Primers were designated 2996, E9/C1 for exons 5 ± 9, 2996, 2997 for exons 5 ± 9, 2996, 2997 for exons 5 ± 6 and E7/C2, E9/C2 for exons 7 ± 9. PCR was performed in a reaction volume of 50 ml in 16 PCR-buer (Promega, Madison, WI, USA) with 3.0 mM MgCl 2 (2996, E9/C1 and E7/C2, E9/C2) or 2.0 mM MgCl 2 (2996, 2997) with 15 pmol of each primer, 200 mM of each dNTP and 1.5 units Taq DNA-polymerase (Promega). Cycling conditions were 948C/3 min (initial denaturation), 948C/30 s, 608C/40 s, 728C/20 ± 60 s (30 cycles) and 728C/ 3 min on a Hybaid Omnigene termal cycler (MWG-Biotech, Ebersberg, Germany). PCR products were puri®ed using the PCR product puri®cation kit from Qiagen (Hilden, Germany) and sequenced using a DyeDeoxy Terminator Cycle sequencing kit (ABI-Perkin Elmer, Weiterstadt, Germany) on an ABI-Prism 310 Genetic Analyzer (ABI-Perkin Elmer). Primers used for PCR and/or sequencing (underlined): 2996: 5'-TATCTGTTCACTTGTGCCCTG-3'; 2997: 5'-CC-ACTGACAACCACCCTTAAC-3'; 2998: 5'-TCATCTTGG-GCCTGTGTTATC-3'; 4780: 5'-TGGTGGGGAGTAGTA-GG-3'; 5252: 5'-TCTTGTCCTGCTTGCTTACCT-3': E5/C1: 5'-CACTTGTGCCCTGACTTTCAAC-3'; E7/C1: 5'-GCAC-AGCAGGCCAGTGTGCAG-3'; E7/C2: 5'-GCTTGCCAC-AGGTCTCCCCAAG-3'; E9/C1: 5'-CGGCATTTTGAGTG-TTAGAC-3'; E9/C2: 5'-CCACTTGATAAGAGGTCCC-3'.
Cell fusion experiments
Cells were grown as described above and prelabelled with uorescent polystyrene microspheres (FluoroSpheres 2 , Molecular Probes, Leiden, Netherlands). The spheres (diameter 0.5 or 1 mm, red or blue¯uorescent) were added to the culture medium (10 ml of aqueous suspension, containing 2% solids, per 15 ml) and get taken up into the cells by phagocytosis. NB and C3H10T cells were mixed in suspension and seeded on microscope slides to yield a nearcon¯uent monolayer with about equal numbers of the two cell types. Fusion was induced by covering the cell layer with a 50% (w/v) solution of polyethyleneglycol (PEG) m.w. 6000 (Sigma, Deisenhofen, Germany) in medium for 60 s at room temperature. PEG solution was then washed o and fresh medium added. Cells were ®xed 2 ± 12 h after fusion and p53 localization analysed by immuno¯uorescence. Only polynucleated cells that contained at least ®ve FluoroSpheres 2 of each colour were taken into account to assure that fusion of two dierent cell types had occurred. Human and murine nuclei were discerned morphologically or by labelling with a monoclonal antibody speci®c for human nucleoli (MAb1277, Hiss Diagnostics, Freiburg, Germany).
Immunohistopathological assays
The tumour tissues were immersed immediately after removal in 4% formalin and then prepared according to standard methods. Serial sections were stained with haematoxylin and eosin and used for immunohistochemical assays. As a positive control for p53 sections from a breast carcinoma with a well-known immunoreactivity with both antibodies were used. Negative controls were obtained by replacing primary antibodies with preimmune mouse serum. After the quenching of endogenous peroxidase with 1% H 2 O 2 for 30 min, serial sections were incubated with 0.5% normal bovine serum to reduce non-speci®c background staining. Thereafter, the slides were incubated with monoclonal antibodies (DO-1, dilution 1 : 1000 or PAb1801, dilution 1 : 1000). For immunostaining, antigens were unmasked by pressure cooking in 10 mM citrate, pH 6, for 5 min. Then slides were incubated with biotinylated secondary antibody at room temperature, followed by incubation with avidin and biotinylated horseradish peroxidase complex (ABC-method, Vector Labs, Burlingame, USA) and ®nally the indirect TSA reagents (Dupont, MA, USA) according the manufacturer's instructions. Peroxidase activity was visualized by 3-amino-9-ethylcarbazole (Sigma) to yield a brown reaction product. The nuclei were slightly counterstained with haematoxylin.
Immunoprecipitation
Preparation of samples and immunoprecipitations were performed essentially as described by Waterman et al. (1998) . Primary antibodies were bound to either Sepharose A or G beads (Pharmacia, Freiburg, Germany) at the following protein amounts per reaction: 1 mg DO-1, PAb1620 (supernatant 1 : 10), or 10 mg PAb421: protein A sepharose; 1 mg of PAb1801, PAb240, Ab-1 (hMDM2), or Ab-1 (p21): protein G sepharose.
Samples were then subjected to standard PAGE and Western blotting, followed by detection with the ECL system (Amersham, Freiburg, Germany).
Electrophoretic gel mobility shift assays (EMSA)
EMSAs were performed as previously described (Halazonetis et al., 1993) .
Determination of transactivation by p53 (mdm2 reporter gene assay)
Reporter plasmids were introduced into cells by transfection with LipofectAMINE 2 (GibcoBRL, Germany) according to the manufacturers instruction. Plasmids used were pGL2NA(mdm2)-luc (from Dr M Oren, Rehovot, Israel), the reporter plasmid carrying the ®re¯y luciferase gene under control of the mdm2 promotor's p53RE and the empty vector pGL3-Basic (Promega, Germany). p53-dependent luciferase activity was normalized against transfection eciency by cotransfection of pC110, constitutively expressing the b-galactosidase gene. 0.2 mg of each plasmid were cotransfected per well of a 6-well plate. After 24 h cells were harvested and luciferase and b-gal activity determined as described previously (Plaumann et al., 1996) .
